LeMaitre Vascular reported preliminary third-quarter 2026 net sales of $68.0 million, an 11% increase from the prior year period, driven by strong graft and shunt volumes. The company posted diluted earnings per share of $0.65 and operating income of $17.7 million. Additionally, the Board approved a quarterly cash dividend of $0.25 per share, payable on December 3, 2026, to shareholders of record as of November 19, 2026. LeMaitre provides devices, implants, and services for the treatment of peripheral vascular disease.
